Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We read with interest the recent work of Leithead and coworkers about the use of non-selective β-blockers (NSBBs) in patients in the transplant waiting list. They studied 322 patients, among those 117 had refractory ascites and observed higher survival rate in those using NSBB, including the ones with refractory ascites (HR mortality=0.35; confidence interval (CI) 95%: 0.14 to 0.86).1 However, the use of NSBB has been a polemic issue since the hypothesis proposed by Krag and coworkers suggesting the existence of a ‘therapeutic window’, according to which NSBB would not be beneficial to patients in early or end-stage cirrhosis with refractory ascites, when it would impair the compensatory cardiac output increase, worsening organ perfusion in decompensated cirrhosis.2
Considering current controversies about the use of propranolol (PPL) in advanced cirrhosis, and its possible deleterious effect on haemodynamic and organ perfusion, we have investigated the endothelial function in patients with …
Contributors The study was designed by AB-A. AB-A, RCC, EdSMF and HSMC gave substantial contributions to patient recruitment and data acquisition. EB conceived the necessary conditions to conduct the study at BioVasc laboratory. Data were analysed by AB-A, RdMP and CAV-N. The report was written by AB-A, RdMP, CAV-N and EB. All authors approved the final version.
Funding Rio de Janeiro State Agency for Research Support (FAPERJ) and National Research Council of Brazil.
Competing interests None declared.
Patient consent Obtained.
Ethics approval Federal University of Rio de Janeiro Ethics Committee.
Provenance and peer review Not commissioned; internally peer reviewed.